Study of Radiotherapy & Pembrolizumab in People With Adrenocortical

See also
Status	Clinical Trial	Phase
Completed	`NCT04373265` - Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)	Phase 1
Recruiting	`NCT06050057` - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting	`NCT03127774` - Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma	Phase 2
Completed	`NCT01048892` - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	Phase 1
Recruiting	`NCT00457587` - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Recruiting	`NCT00669266` - Adrenal Tumors - Pathogenesis and Therapy
Recruiting	`NCT05999292` - Phase 1 Study of 68Ga-R8760	Phase 1
Completed	`NCT05361083` - First-in-human Evaluation of [18F]CETO	Early Phase 1
Recruiting	`NCT05660889` - Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
Completed	`NCT00003038` - Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors	Phase 1
Enrolling by invitation	`NCT03474237` - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Enrolling by invitation	`NCT05036434` - Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma	Phase 2
Terminated	`NCT05012397` - Milademetan in Advanced/Metastatic Solid Tumors	Phase 2
Not yet recruiting	`NCT06333314` - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI	Phase 2
Withdrawn	`NCT00469469` - Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma	Phase 2
Completed	`NCT00002608` - Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	Phase 2
Not yet recruiting	`NCT05839886` - The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
Recruiting	`NCT05634577` - A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma	Phase 2
Completed	`NCT00454103` - Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy	Phase 1/Phase 2

NCT number	NCT06066333
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Nitya Raj, MD
Phone	646-888-4849
Email	rajn@mskcc.org
Status	Recruiting
Phase	Phase 2
Start date	September 27, 2023
Completion date	September 27, 2026

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms